Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE9.0150
- TODAY'S CHANGE (%)0.1150 (1.2921%)
- Bid / Lots8.9800/ 4
- Ask / Lots9.0500/ 35
- Open / Previous Close8.9900 / 8.9000
- Day Range
- 52 Week Range
- Volume233,226
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 7130 | 9 |
| 09:34 ET | 5268 | 9.025 |
| 09:36 ET | 7765 | 9.05 |
| 09:38 ET | 7039 | 8.95 |
| 09:39 ET | 4544 | 8.9201 |
| 09:41 ET | 950 | 8.945 |
| 09:43 ET | 6061 | 8.935 |
| 09:45 ET | 5907 | 8.85 |
| 09:48 ET | 2450 | 8.77 |
| 09:50 ET | 11222 | 8.6786 |
| 09:52 ET | 3824 | 8.8 |
| 09:54 ET | 300 | 8.755 |
| 09:56 ET | 1000 | 8.685 |
| 09:57 ET | 9416 | 8.6101 |
| 09:59 ET | 2309 | 8.61 |
| 10:01 ET | 700 | 8.645 |
| 10:03 ET | 4050 | 8.75 |
| 10:06 ET | 6759 | 8.77 |
| 10:08 ET | 2923 | 8.77 |
| 10:10 ET | 1569 | 8.74 |
| 10:12 ET | 8545 | 8.67 |
| 10:14 ET | 3600 | 8.7 |
| 10:15 ET | 2020 | 8.72 |
| 10:17 ET | 2062 | 8.7373 |
| 10:19 ET | 2320 | 8.7374 |
| 10:21 ET | 500 | 8.68 |
| 10:24 ET | 2997 | 8.69 |
| 10:26 ET | 200 | 8.7 |
| 10:28 ET | 2286 | 8.76 |
| 10:30 ET | 650 | 8.73 |
| 10:32 ET | 808 | 8.75 |
| 10:33 ET | 540 | 8.78 |
| 10:35 ET | 3545 | 8.81 |
| 10:37 ET | 1500 | 8.85 |
| 10:39 ET | 19769 | 8.9699 |
| 10:42 ET | 1676 | 8.92 |
| 10:44 ET | 2036 | 8.87 |
| 10:46 ET | 6144 | 8.8834 |
| 10:48 ET | 700 | 8.91 |
| 10:50 ET | 553 | 8.9303 |
| 10:51 ET | 651 | 8.97 |
| 10:53 ET | 1282 | 8.96 |
| 10:55 ET | 2600 | 8.9999 |
| 10:57 ET | 3652 | 8.9492 |
| 11:00 ET | 700 | 8.96 |
| 11:02 ET | 2692 | 8.99 |
| 11:04 ET | 400 | 8.96 |
| 11:08 ET | 3735 | 9.0124 |
| 11:09 ET | 800 | 9.015 |
Today
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
DJ Candel Therapeutics Shares Pop 39% After Lung-Cancer Treatment Yields Higher Survival in Trial, from 7:16PM ET on Thursday May 23, 2024 by Dow Jones
7:16PM ET on Thursday May 23, 2024 by Dow JonesCandel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting, from 5:00PM ET on Thursday May 23, 2024 by Dow Jones
5:00PM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 264.7M | -7.0x | --- |
ATAI Life Sciences NV | 262.8M | -6.7x | --- |
Black Diamond Therapeutics Inc | 268.9M | -2.8x | --- |
Inovio Pharmaceuticals Inc | 262.5M | -1.9x | --- |
Rani Therapeutics Holdings Inc | 277.3M | -4.2x | --- |
Monte Rosa Therapeutics Inc | 250.7M | -1.7x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $264.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
